BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26438155)

  • 1. Systemic Administration and Targeted Radiosensitization via Chemically Synthetic Aptamer-siRNA Chimeras in Human Tumor Xenografts.
    Ni X; Zhang Y; Zennami K; Castanares M; Mukherjee A; Raval RR; Zhou H; DeWeese TL; Lupold SE
    Mol Cancer Ther; 2015 Dec; 14(12):2797-804. PubMed ID: 26438155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.
    Ni X; Zhang Y; Ribas J; Chowdhury WH; Castanares M; Zhang Z; Laiho M; DeWeese TL; Lupold SE
    J Clin Invest; 2011 Jun; 121(6):2383-90. PubMed ID: 21555850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.
    Dassie JP; Liu XY; Thomas GS; Whitaker RM; Thiel KW; Stockdale KR; Meyerholz DK; McCaffrey AP; McNamara JO; Giangrande PH
    Nat Biotechnol; 2009 Sep; 27(9):839-49. PubMed ID: 19701187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
    Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
    Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
    Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
    Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
    Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
    Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles.
    Fan X; Guo Y; Wang L; Xiong X; Zhu L; Fang K
    Int J Nanomedicine; 2016; 11():3939-50. PubMed ID: 27574424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery.
    Leach JC; Wang A; Ye K; Jin S
    Int J Mol Sci; 2016 Mar; 17(3):380. PubMed ID: 26985893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boranophosphate siRNA-aptamer chimeras for tumor-specific downregulation of cancer receptors and modulators.
    Shaw BR; Moussa L; Sharaf M; Cheek M; Dobrikov M
    Nucleic Acids Symp Ser (Oxf); 2008; (52):655-6. PubMed ID: 18776550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer.
    Shi SJ; Wang LJ; Han DH; Wu JH; Jiao D; Zhang KL; Chen JW; Li Y; Yang F; Zhang JL; Zheng GX; Yang AG; Zhao AZ; Qin WJ; Wen WH
    Theranostics; 2019; 9(5):1247-1263. PubMed ID: 30867828
    [No Abstract]   [Full Text] [Related]  

  • 11. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.
    McNamara JO; Andrechek ER; Wang Y; Viles KD; Rempel RE; Gilboa E; Sullenger BA; Giangrande PH
    Nat Biotechnol; 2006 Aug; 24(8):1005-15. PubMed ID: 16823371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.
    Cho S; Zammarchi F; Williams DG; Havenith CEG; Monks NR; Tyrer P; D'Hooge F; Fleming R; Vashisht K; Dimasi N; Bertelli F; Corbett S; Adams L; Reinert HW; Dissanayake S; Britten CE; King W; Dacosta K; Tammali R; Schifferli K; Strout P; Korade M; Masson Hinrichs MJ; Chivers S; Corey E; Liu H; Kim S; Bander NH; Howard PW; Hartley JA; Coats S; Tice DA; Herbst R; van Berkel PH
    Mol Cancer Ther; 2018 Oct; 17(10):2176-2186. PubMed ID: 30065100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice.
    Langut Y; Talhami A; Mamidi S; Shir A; Zigler M; Joubran S; Sagalov A; Flashner-Abramson E; Edinger N; Klein S; Levitzki A
    Proc Natl Acad Sci U S A; 2017 Dec; 114(52):13655-13660. PubMed ID: 29229829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo.
    Hao Z; Fan W; Hao J; Wu X; Zeng GQ; Zhang LJ; Nie SF; Wang XD
    Drug Deliv; 2016; 23(3):874-81. PubMed ID: 24892627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer.
    Liu HY; Yu X; Liu H; Wu D; She JX
    Sci Rep; 2016 Jul; 6():30346. PubMed ID: 27456457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2.
    Wullner U; Neef I; Eller A; Kleines M; Tur MK; Barth S
    Curr Cancer Drug Targets; 2008 Nov; 8(7):554-65. PubMed ID: 18991566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer.
    Xiang B; Dong DW; Shi NQ; Gao W; Yang ZZ; Cui Y; Cao DY; Qi XR
    Biomaterials; 2013 Sep; 34(28):6976-91. PubMed ID: 23777916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers.
    Min K; Jo H; Song K; Cho M; Chun YS; Jon S; Kim WJ; Ban C
    Biomaterials; 2011 Mar; 32(8):2124-32. PubMed ID: 21147500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-selective gene silencing in prostate cancer LNCap cells using prostate-specific membrane antigen promoter and enhancer in vitro and in vivo.
    Liu R; Sun J; Zhang Z; Xu Y
    Cell Biol Int; 2012 Oct; 36(10):863-72. PubMed ID: 22612256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery.
    Gu F; Langer R; Farokhzad OC
    Methods Mol Biol; 2009; 544():589-98. PubMed ID: 19488725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.